# ASX Announcement

## Race executes agreement with Ardena

## for GMP manufacturing of RC220

- **Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation**
- **Ardena has a long track record of providing sterile injectable products for all stages of clinical development**
- **Partnership strengthens the existing manufacturing programs by serving as a primary source for EU compliant supplies required for EU clinical studies, while also providing a backup source for US and Australian clinical programs.**

---

**12 July 2023** – Race Oncology Limited ("Race") is pleased to announce that it has signed an agreement with leading global contract development and manufacturing organisation (CDMO), Ardena Holding NV (Ardena) to provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race's flagship intravenous (IV) formulation of bisantrene, RC220.

Ardena is a fully integrated CDMO which assists biopharma companies with services spanning the drug development life cycle. The company has a long track record of providing sterile injectable products for all stages of clinical development.

The partnership strengthens Race's existing manufacturing programs by serving as a primary source for EU compliant supplies of RC220 required for EU clinical studies. It also provides a backup source for US and Australian clinical programs.

**CEO and Managing Director, Damian Clarke-Bruce commented:** *"We are pleased to welcome Ardena as a manufacturing partner, adding to our existing contracted manufacturing capability. Ardena's position in Europe ensures ease of access to RC220 product for our European clinical trials and adds a second source of FDA-compliant pharmaceutical grade product."*

The initial development budget contracted is approximately USD $1m. Ardena is expected to provide Race's first EU and international compliant GMP supplies with goal of completion being by the end of 2023. Technology transfer to formally commence the program will occur in the coming months.

The agreement with Ardena is for an initial period of 5 years and shall then be automatically extended for successive one year periods unless terminated earlier in accordance with the terms of the agreement.

--ENDS--

## About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called bisantrene.

Bisantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that bisantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for bisantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of bisantrene. Learn more at www.raceoncology.com

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub https://announcements.raceoncology.com

*Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.*

## About Ardena

Ardena is a multi-service CDMO, assisting biopharma companies with services spanning the full development life cycle. The Company offers a comprehensive 'Make, Analyze, File' model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development.

With a strong reputation for quality and a flexible service delivery model, Ardena caters to a highly diversified base of over 300 customers throughout Europe, the US, Japan and Korea. A high science approach and broad drug development toolkit differentiate Ardena from peers as a comprehensive multi-service pan-European platform. For more information, please visit www.ardena.com

**Release authorised by:**

Damian Clarke-Bruce, CEO/MD on behalf of the Race Board of Directors

damian.clarke-bruce@raceoncology.com

**Media contact:**

Jane Lowe

+61 411 117 774

jane.lowe@irdepartment.com.au